MyopiaPhase 2NCT07863713
Early Intervention for High Risk Premyopic Children
A Phase 2 study testing 0.025% atropine eye drops and DIMS TED in people with Myopia, run by National Yang Ming Chiao Tung University Hospital.
Trial summary
The purpose of this research project is to add evidence of pharmacological (0.025% atropine) and optical (Defocus Integrated Multiple Segments Triple Enhanced Design spectacle lenses ) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention… Read more about this study
- Who is it for?
- Ages 5 to 6 yearsHealthy volunteers can take part
- Conditions the study is for
- Myopia
- What is being tested?
- 0.025% atropine eye drops and DIMS TED
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 240 participants
- Where
- No sites listed yet
- Study dates
- 24 Oct 2026to 24 Oct 2033
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 6 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Age at enrollment: 5-6 years old (the senior grade of kindergarten)
- Cycloplegic SE of the eye with less SE (less positive or more negative refractive error): < +1.00 D and > -0.50 D
- Astigmatism: 1.5 D or less in both eyes
- Anisometropia: 1.50 D or less
- Monocular uncorrected visual acuity: 6/7.5 or better in both eyes
- Either of the parents with moderate myopia
- Acceptance of random group allocation
- Submission of complete informed consent.
Who cannot join
- Strabismus or any ocular motility disorder
- Any ophthalmic and systemic disorders that might affect visual functions or refractive development
- Previous treatment of atropine or other myopia control intervention
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
DR. contact
About this study
Official title: Early Intervention for High Risk Premyopic Children: A Comparison Study of Defocus Integrated Multiple Segments Triple Enhanced Design Spectacle Lenses, 0.025% Atropine and Usual Care for Myopia Prevention
The purpose of this research project is to add evidence of pharmacological (0.025% atropine) and optical (Defocus Integrated Multiple Segments Triple Enhanced Design spectacle lenses ) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention strategy for myopia control in premyopic children.
Read the detailed description
With the increasing popularity of screen-based digital devices in the post-pandemic era, childhood myopia prevention and control has become a growing global challenge. Although the protective effect of increased outdoor time has been well established, the optimal strategy for preventing or delaying the onset of childhood myopia remains to be determined, particularly among pre-myopic children around the age of school entry. A substantial increase in myopia prevalence has been reported before and after entry into elementary school, and children with early-onset myopia are at increased risk of rapid progression and subsequent development of high myopia later in life.
Recent evidence suggests that low-concentration atropine eye drops may reduce the incidence of childhood myopia. However, photophobia and other dose-related adverse effects associated with higher concentrations of atropine may interfere with daytime visual activities and potentially reduce children's willingness to engage in outdoor activities. In addition, evidence regarding optical interventions for the prevention of myopia onset remains limited.
These unmet clinical needs motivate us to propose a randomized controlled trial evaluating optical and pharmacological approaches for myopia prevention using Defocus Incorporated Multiple Segments Triple Enhanced Design (DIMS TED) spectacle lenses and 0.025% atropine eye drops, respectively, in pre-myopic preschool children aged 5-6 years.
In this proposed study, we plan to recruit a total of 240 eligible participants identified as pre-myopic and asymptomatic through a population-based eye care program in Yilan County. Eligible participants will be randomly assigned to three groups: the DIMS TED spectacle lens group (n=80), the 0.025% atropine group (n=80), and the usual-care group (n=80).
Because environmental and near-work demands are generally lower during preschool than after entry into elementary school, children assigned to the DIMS TED group will be instructed to wear the spectacles using a stepwise strategy: primarily at home and during near-work activities during the preschool stage, followed by full-time wear after entering elementary school.
Cycloplegic spherical equivalent (SE) refraction and axial length will be measured every 6 months during the 7-year follow-up period. The primary outcome will be the change in mean cycloplegic SE over the study period among the three groups. Secondary outcomes will include the cumulative incidence of myopia, the cumulative proportion of participants exhibiting a fast myopic shift in SE, and changes in mean axial length over the study period.
This proposed project may provide further evidence regarding early optical and pharmacological intervention strategies for myopia prevention and may support the development of an eye-care model emphasizing early identification and intervention for pre-myopic preschool children before or around the time of elementary school entry.
- Conditions
- Myopia
- Being tested
- 0.025% atropine eye drops, DIMS TED
- Keywords
- myopia, DIMS TED, Atropine, Outdoor activities
- Medical subject headings
- Myopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
0.025% atropine eye dropsDrug
Daily instillation of 0.025% atropine
DIMS TEDDevice
Stepwise wearing of DIMS TED
| Study group | Role | What they receive |
|---|---|---|
| DIMS TED | Active comparator | Stepwise wearing of DIMS TED Receives: Device: DIMS TED |
| 0.025% Atropine | Active comparator | Daily administration of 0.025% Atropine Receives: Drug: 0.025% atropine eye drops |
| Normal activities | No intervention | Normal promotion of outdoor activities |
What is being measured
The primary outcome is the main question the study is designed to answer.
Myopic shift of spherical equivalent refraction
The change of mean cycloplegic spherical equivalent refraction over 7 years
Measured: 7 years
Secondary outcomes (4)
Axial length elongation
The change of mean axial length over 7 years
Measured: 7 years
Incidence of myopia
the cumulative percentage of incident myopia
Measured: 7 years
Fast myopic shift of spherical equivalent refraction
the cumulative percentage of fast myopic shift of spherical equivalent refraction
Measured: 7 years
Subfoveal choroidal thickness
the vertical distance from the outer edge of the retinal pigment epithelium (or Bruch's membrane) to the inner surface of the sclera (the chorioscleral border) directly beneath the fovea
Measured: 7 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start24 Oct 2026 (estimated)
- Primary completion24 Oct 2033 (estimated)
- Study completion24 Oct 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MyopiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Yang Ming Chiao Tung University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Der-Chong Tsai, MD PhD, National Yang Ming Chiao Tung University Hospital
- Investigators
- Hsin-Yu Yang, Principal investigator, National Yang Ming Chiao Tung University Hospital, Yilan, Taiw
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07863713
- Sponsor's protocol ID
- Premyopia PQR study
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No